Arbutus Biopharma Corp (ABUS) stock is up 52.00% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives ABUS stock a score of 70 out of a possible 100.
That rank is primarily influenced by a fundamental score of 82. In addition to the average rating from Wall Street analysts, ABUS stock has a mean target price of 7. This means analysts expect the stock to rise 67.46% over the next 12 months. ABUS's rank also includes a short-term technical score of 70. The long-term technical score for ABUS is 58.
What's Happening with ABUS Stock Today
Arbutus Biopharma Corp (ABUS) stock is lower by -3.91% while the S&P 500 is lower by -1.73% as of 10:35 AM on Monday, Dec 21. ABUS is lower by -$0.17 from the previous closing price of $4.35 on volume of 2,294,414 shares. Over the past year the S&P 500 has risen 13.07% while ABUS is up 52.00%. ABUS lost -$1.24 per share in the over the last 12 months.